OBJECTIVE:To probe into the efficacy of ossotide for injection combined with Alendronate tablets in treatment of primary osteoporosis .METHODS: 100 patients with primary osteoporosis admitted into Hubei Rongjun Hospital from Jan.2014 to Jan.2017 were selected and divided into observation group and control group via random number table, with 50 cases in each.The control group was treated with Calcium carbonate and vitamin D 3 tablets, while the observation group was given ossotide for injection combined with Alendronate tablets based on the control group.Both groups were given a 6-month treatment.Clinical efficacy,bone density and pain scoring before and after treatment , and incidences of adverse drug reactions between two groups were compared .RESULTS:The total effective rate of observation group (94％, 47/50) was significantly higher than that of the control group (78％, 39/50), with statistically significant difference (P0.05).CONCLUSIONS: The efficacy of ossotide for injection combined with Alendronate tablets in treatment of primary osteoporosis is remarkable , which can increase patients bone densities and relieve pain , with high safety .%目的:探讨注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效.方法:选取2014年1月—2017年1月湖北省荣军医院收治的原发性骨质疏松症患者100例作为研究对象,以随机数字表法分为观察组和对照组,每组50例.对照组患者给予碳酸钙D3片治疗,观察组患者在对照组的基础上加用注射用骨肽联合阿仑膦酸钠片治疗.两组患者均治疗6个月.比较两组患者的临床疗效,治疗前后骨密度、疼痛评分及不良反应发生情况.结果:观察组患者的总有效率为94％(47/50),明显高于对照组的78％(39/50),差异有统计学意义(P0.05).结论:注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效显著,可增加患者骨密度,缓解患者疼痛,安全性高.
展开▼
